

AVIZAT,

Director IOSUD

Prof.univ.dr. Ionica ONCIOIU

AVIZAT,

Director CSD

Conf.univ.dr. Magdalena BUDISTEANU

**Fișa de îndeplinire a standardelor I.O.S.U.D.
Universitatea Titu Maiorescu din București
în vederea obținerii atestatalui de abilitare****NUME: ANDREESCU MIHAELA, nume anterioare Tevet, Closca-Gheorghiu**
Medic primar Hematologie
Doctor în Medicină**COMISIA DE MEDICINĂ***Standarde minime necesare și obligatorii pentru conferirea titlurilor didactice din învățământul superior
și a gradelor profesionale de cercetare-dezvoltare**(Se completează descriptiv incluzând toți itemii care intră în compunerea punctajului)*

Titlul	Nr. Articole ISI Autor principal	Nr. Articole ISI Coautor	Index Hirsch (WOS)	Factor cumulat de impact autor principal (FCIAP)
Abilitare	15	12	8	31,7

Total citări WOS: 188 | Publicații WOS Core Collection: 71 | H-index WOS: 8 |**Articole cotate ISI (Web of Science Core Collection) în calitate de
autor principal: Nr articole: 15 (minim 10)***Ordonate pe ani (descrescător). Q = Quartila revistei, IF = Factor de Impact.**Notă: Toate articolele din această secțiune au fost publicate sub numele **Andrescu M** (2023–2025).*

Nr.	Autori (Numele publicat)	Titlu	Revista / Q / IF / Citări
2025			
1	Andrescu M, Tanase A, Andrescu B, Moldovan C <i>[publicat ca: Andrescu M]</i>	A Review of Immunological Evaluation of Patients with Recurrent Spontaneous Abortion (RSA) [https://doi.org/10.3390/ijms26020785]	Int J Mol Sci, 2025, 26(2):785, Q2, IF 4.9, 7 citări
2	Andrescu M, Tudorache SI, Voiculescu OM, Andrescu B	IL-4 and Brentuximab Vedotin in Mycosis Fungoides: A Perspective on Potential Therapeutic Targets [https://doi.org/10.3390/cimb47080586]	Curr Issues Mol Biol, 2025, 47(8):586, Q2, IF 3.0, 0 citări

[publicat ca: Andreescu M]

2024

3	Andreescu M [publicat ca: Andreescu M]	Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies [https://pubmed.ncbi.nlm.nih.gov/38179322/]	Cureus, 2024, 16(1):e51662, Q2, IF 1.3, 4 citări
4	Andreescu M [publicat ca: Andreescu M]	Correlation Between Maternal-Fetus Interface and Placenta-Mediated Complications [https://pubmed.ncbi.nlm.nih.gov/38882223/]	Cureus, 2024, 16(6):e62457, Q2, IF 1.3, 3 citări
5	Andreescu M, Andreescu B [publicat ca: Andreescu M]	A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery [https://pubmed.ncbi.nlm.nih.gov/38606222/]	Cureus, 2024, 16(3):e56008, Q2, IF 1.3, 3 citări
6	Andreescu M, Moldovan C, Lespezeanu DA et al. [publicat ca: Andreescu M]	COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern - Mixed-Method Systematic Review [https://pubmed.ncbi.nlm.nih.gov/38312523/]	Infect Drug Resist, 2024, 17:387-402, Q2, IF 2.9, 2 citări
7	Andreescu M, Andreescu B [publicat ca: Andreescu M]	Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy [https://pubmed.ncbi.nlm.nih.gov/38384647/]	Cureus, 2024, 16(1):e52737, Q2, IF 1.3, 0 citări

2023

8	Andreescu M, Frincu F, Plotogea M, Mehedintu C [publicat ca: Andreescu M]	Recurrent Abortion and the Involvement of Killer-Cell Immunoglobulin-like Receptor (KIR) Genes, Activated T Cells, NK Abnormalities, and Cytokine Profiles [https://pubmed.ncbi.nlm.nih.gov/36835892/]	J Clin Med, 2023, 12(4):1355, Q1, IF 3, 16 citări
9	Andreescu M [publicat ca: Andreescu M]	The impact of the use of immunosuppressive treatment after an embryo transfer in increasing the rate of live birth [https://pubmed.ncbi.nlm.nih.gov/37441690/]	Front Med, 2023, 10:1167876, Q1, IF 3.1, 12 citări
10	Andreescu M [publicat ca: Andreescu M]	Molecular Insights Into the Role of Gut Microbiota in Antibiotic Therapy Selection and Resistance Mitigation [https://pubmed.ncbi.nlm.nih.gov/38089944/]	Cureus, 2023, 15(12):e50318, Q3, IF 1.3, 9 citări
11	Andreescu M [publicat ca: Andreescu M]	Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies [https://pubmed.ncbi.nlm.nih.gov/37374055/]	Life, 2023, 13(6):1272, Q1, IF 3.2, 4 citări
12	Andreescu M [publicat ca: Andreescu M]	Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management [https://pubmed.ncbi.nlm.nih.gov/38033434/]	Cureus, 2023, 15(11):e49696, Q3, IF 1.3, 2 citări
13	Andreescu M [publicat ca: Andreescu M]	The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutic targets [https://doi.org/10.3389/frhem.2023.1191178]	Front Hematol, 2023, 2:1191178, Q4, IF 0.6, 4 citări
14	Andreescu M, Berbec N, Tanase AD [publicat ca: Andreescu M]	Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy in CLL [https://doi.org/10.3390/icm12072731]	J Clin Med, 2023, 12(7):2731, Q1, IF 3.0, 2 citări
15	Andreescu M, Zurac S, Lacatusu A et al. [publicat ca: Andreescu M]	Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin's lymphoma [https://rrml.ro/articole/articol.php?year=2023&vol=1&poz=7]	Rev Romana Med Lab, 2023, 31(1):59-64, Q4, IF 0.5, 0 citări

Factor de impact cumulativ articole autor principal: IF = 31.7 (68 citări)

Articole cotate ISI (Web of Science Core Collection) în calitate de coautor: Nr articole: 12 (minim 5)

Ordonate pe ani (descrescător). Q = Quartila revistei, IF = Factor de Impact.

Notă: Articolele din 2012–2016 au fost publicate sub numele **Tevet M**, cele de după 2017 sub numele **Andreescu M**.

Nr.	Autori (Numele publicat)	Titlu	Revista / Q / IF / Citări
2025			
1	Padurariu-Covit MD, Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	Managing HIV-Associated Hodgkin Lymphoma During the COVID-19 Pandemic: Case Report and Literature Review [https://doi.org/10.3390/v17030404]	Viruses, 2025, 17(3):404, Q2, IF 3.5, 2 citări
2	Padurariu-Covit MD, Georgescu C, ... Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions [https://doi.org/10.3390/v17121615]	Viruses, 2025, 17(12):1615, Q2, IF 3.5, 0 citări
3	Brehar FM, Patrascan AM, ... Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	Intraventricular mass in a 52-year-old woman [https://pubmed.ncbi.nlm.nih.gov/40064631/]	Brain Pathol, 2025, 35(3):e70003, Q1, IF 6.2, 0 citări
2024			
4	Plotogea M, Zgura A, ... Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	Women's Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship [https://doi.org/10.3390/life14010035]	Life, 2024, 14(1):35, Q1, IF 3.2, 3 citări
2021			
5	Omer M, Vladareanu AM, Popov VM, Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia [https://www.rml.ro/articole/articol.php?year=2021&vol=4&poz=3]	Rev Romana Med Lab, 2021, 29(4):395-402, Q4, IF 0.8, 1 citări
2020			
6	Tanase AD, Colita A, ... Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma – Romanian Experience [https://doi.org/10.3390/icm9082417]	J Clin Med, 2020, 9(8):2417, Q2, IF 4.24, 14 citări
2018			
7	Trifa AP, Banescu C, ... Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients [https://pubmed.ncbi.nlm.nih.gov/29047144/]	Am J Hematol, 2018, 93(1):100-106, Q1, IF 2.16, 31 citări
8	Trifa AP, Banescu C, ... Andreescu M et al. <i>[publicat ca: Andreescu M]</i>	Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia [https://pubmed.ncbi.nlm.nih.gov/30249383/]	Blood Cells Mol Dis, 2018, 73:45-46, Q2, IF 1.7, 6 citări
2016			
9	Trifa AP, Banescu C, ... Tevet M et al. <i>[publicat ca: Tevet M]</i>	TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms – a multicentric study on 529 patients [https://pubmed.ncbi.nlm.nih.gov/27061303/]	Br J Haematol, 2016, 174(2):218-226, Q1, IF 5.67, 33 citări
10	Trifa AP, Banescu C, ... Tevet M et al. <i>[publicat ca: Tevet M]</i>	Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and	Hematology, 2016, 21(9):520-525, Q3, IF 2.27, 8 citări

GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms

[<https://pubmed.ncbi.nlm.nih.gov/27077777/>]

2015

- | | | | |
|----|---|---|--|
| 11 | Trifa AP, Popp RA, Tevel M et al
<i>[publicat ca Tevel M]</i> | CALR versus JAK2 mutated essential thrombocythaemia – a report on 141 patients
[https://pubmed.ncbi.nlm.nih.gov/25103987/] | Br J Haematol, 2015, 168(1): 151-153, Q1, IF 4.97, 16 citări |
| 12 | Mastaler B, Deaconescu V, Tevel M et al
<i>[publicat ca Tevel M]</i> | Multiple Intestinal Lymphoma
[https://pubmed.ncbi.nlm.nih.gov/26076564/] | Rom J Intern Med, 2015, 53(1): 83-87, Q4, IF 1.4, 8 citări |

Factor de impact cumulart articole coautor: IF = 39.61 (122 citări)

Data:

29.01.2026

Se [redacted] candidatului,

Conf. univ. dr. [redacted] ANDREESCU